Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs

Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker... Key PointsQuestionDoes obesity mediate response to sodium channel vs potassium channel blocker antiarrhythmic drugs in patients with atrial fibrillation and in mice with diet-induced obesity? FindingsIn this cohort study of 311 patients, those with obesity had greater recurrence (30%) of atrial fibrillation compared with those who were not obese who received sodium channel blocker antiarrhythmic drugs (6%); significant factors associated with failure to respond to antiarrhythmic drugs were use of sodium channel blockers, obesity, female sex, and hyperthyroidism. Mice with obesity showed reduced association of flecainide acetate in suppressing pacing-induced atrial fibrillation vs sotalol hydrochloride. MeaningPossible reduced response to sodium channel blocker antiarrhythmic drugs in suppressing atrial fibrillation in patients with obesity has important clinical implications. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs

Loading next page...
 
/lp/american-medical-association/association-between-obesity-mediated-atrial-fibrillation-and-therapy-IYSvMBi7sz

References (35)

Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2019.4513
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionDoes obesity mediate response to sodium channel vs potassium channel blocker antiarrhythmic drugs in patients with atrial fibrillation and in mice with diet-induced obesity? FindingsIn this cohort study of 311 patients, those with obesity had greater recurrence (30%) of atrial fibrillation compared with those who were not obese who received sodium channel blocker antiarrhythmic drugs (6%); significant factors associated with failure to respond to antiarrhythmic drugs were use of sodium channel blockers, obesity, female sex, and hyperthyroidism. Mice with obesity showed reduced association of flecainide acetate in suppressing pacing-induced atrial fibrillation vs sotalol hydrochloride. MeaningPossible reduced response to sodium channel blocker antiarrhythmic drugs in suppressing atrial fibrillation in patients with obesity has important clinical implications.

Journal

JAMA CardiologyAmerican Medical Association

Published: Jan 27, 2020

There are no references for this article.